









HEALTH-ECONOMIC MODELLING OF INFECTIOUS DISEASE DIAGNOSTICS: CURRENT APPROACHES AND FUTURE OPPORTUNITIES


Simon van der Pol, Paula Rojas, Carmelo Juárez, Thea van Asselt, Fernando Antoñanzas, Maarten Postma University Medical Center Groningen (the Netherlands), University of La Rioja (Spain)

Background

Antimicrobial resistance (AMR) is a public health threat; infections with resistant organisms are estimated to cause over 650.000 infections and over 30.000 deaths in Europe¹. AMR is associated with antibiotic consumption: appropriate prescribing of antibiotics is key in combating AMR^{2,3}. To fight this threat, it has been suggested that point-of-care diagnostics inform antibiotics to prescribing are an important tool in reducing antibiotics prescriptions.

Main objectives With the objective of knowing the state of the art on diagnostic, health-economic models, we reviewed costanalyses (CEAs) on diagnostics for effectiveness infectious disease, focusing on model types and AMR.

General conclusions of articles in two disease areas*




Key **Findings**

Most cost-effectiveness analyses dealing with diagnostics are for certain types of respiratory tract infections: such general respiratory tract infections, influenza or tuberculosis. Sexual transmitted disease, malaria and gastroenteritis (e.g. helicobacter infections) are also common disease groups.

Although bacterial or viral resistance is often discussed in the included papers, it is rarely included in the analysis. Examples of methods to include resistance are: an ICER with prescriptions saved as an outcome; calculating the threshold cost of resistance that would change the conclusion of cost-effectiveness; or a point estimate of resistant pathogens.

Flow chart of paper inclusion




Methods

searched the literature comprehensively through the PUBMED, Web of Science and EMBASE databases, as well as grey literature for the period 2000-2018. We included economic evaluations for diagnostic strategies for infectious disease in all geographic areas. Studies dealing with (population) screenings or disease monitoring were explicitly excluded. Data extraction was based on the CHEERS checklist⁴, using a standardized digital (Google) form, with an emphasis on model types and inclusion of AMR.

Results

The flow diagram of included articles is shown above. Most papers are set in the primary care setting, followed by the hospital setting. A large majority of papers analyzed use a decision tree model for the calculation of qualityadjusted life years (QALYs) and costs. Often, these models use shorter time horizons, (e.g. one flu season), rather than a lifetime approach. The disease types investigated are shown in the pie chart below. Looking at the author's conclusions (see figure to the left), influenza diagnostics are not costeffective in 50% of the articles, but for respiratory infections, improved diagnostics always is cost-effective or cost-saving.

Pie chart of disease types included in systematic review



References

- Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2018;0(0). doi:10.1016/S1473-3099(18)30605-42
- Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14(1):13. doi:10.1186/1471-2334-14-13
- 3. Aryee A, Price N. Antimicrobial stewardship can we afford to do without it? Br J Clin Pharmacol. 2015;79(2):173-181. doi:10.1111/bcp.12417
- Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049. doi:10.1136/bmj.f1049

BibTeX file for articles included in review: https://tinyurl.com/y423k22k





www.imi.Europa.eu www.value-dx.eu

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.



















